Navigation Links
Oncomine(TM) Again Key to Prostate Cancer Discovery
Date:6/10/2008

Cancer Cell Report Identifies SPINK1 as a New Biomarker for Prostate Cancer

ANN ARBOR, Mich., June 10 /PRNewswire/ -- Compendia Bioscience, Inc., the leading provider of cancer profiling data and analysis tools, today announced the central role of their flagship product Oncomine(TM) in the discovery and identification of SPINK1 as a key new therapeutic target and biomarker for prostate cancer.

Oncomine is a rapidly growing compendium of nearly 26,000 gene expression and DNA copy number arrays coupled with analysis functions and a web application for data mining and visualization. Comprised of thousands of samples representing every major type of cancer, Oncomine exploits this data for therapeutic target discovery, validation, and prioritization.

Compendia CEO Daniel R. Rhodes, Ph.D., in his continued role as a research investigator at the University of Michigan, led the Oncomine analysis that identified SPINK1 as a candidate oncogene in prostate cancer. Further experimental work by many of the same scientists that previously identified ETS-family gene fusions in prostate cancer using Oncomine led to this discovery.

"We extended an approach called Cancer Outlier Profile Analysis (COPA) that had previously led us to identify ETS-family gene fusions in prostate cancer," said Dr. Rhodes. "We knew from that experience that true oncogenes are likely to appear in COPA results from multiple independent datasets. Therefore, we intentionally looked for genes that had high COPA ranks across multiple datasets and SPINK1 looked interesting. Further Oncomine analysis showed that SPINK1 over-expression was mutually exclusive with ETS-family gene fusion events and was not present in normal prostate tissue. So, we were pretty sure we had found something important."

Published in the current edition of Cancer Cell (Volume 13 Issue 6: June 2008), this study shows that SPINK1 is detectable in the urine and that SPINK1-positive prostate cancers are a particularly aggressive molecular subset of prostate cancer with SPINK1 having a role in cancer invasion.

The analysis approach used to identify SPINK1 has been named Meta-COPA and will soon become a standard feature within the Oncomine platform. In the interim, Compendia Bioscience will provide scientific services to answer customers' key research questions requiring Meta-COPA or other analyses not currently addressable through the Oncomine user interface.

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. The Oncomine Platforms are used by thousands of cancer researchers worldwide in both academic institutions as well as biotech and pharmaceutical companies to advance the molecular understanding of cancer and cancer treatment. http://www.compendiabio.com


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Compendia Bioscience Announces the Release and Availability of Oncomine(TM) Research Premium Edition
2. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
4. MultiVu Video Feed: Hard Rocks 2007 Ambassadors of Rock Tour Is "On the Road Again" With Music Legend Willie Nelson
5. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
6. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
7. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. N-Viro International Corporation Announces Dismissal of Lawsuit Against It
9. Sticky mussels inspire biomedical engineer yet again
10. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
11. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of ... offering. ... The Global Market for Bioproducts Should Reach $714.6 Billion ... of 8.9%, This research report quantifies the ... product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite ...
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX), a ... market, today reported financial results for the quarter ... provide an update on the company,s clinical development ... "We are pleased to report that last year ... President Anja Krammer. "We achieved key clinical milestones ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , ... software globally, announces significant enhancements to new and core ... 2016. New products include mobile and desktop Acuant FRM ... TM - a real time manual review of ... idScan® technology provides the fastest and most accurate capture ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):